Latest News

STAT Plus: Pharmalittle: AstraZeneca stumbles in lung cancer; FDA official on Novartis data scandal says ‘we got lucky’

Rise and shine, everyone, the middle of the week is already here. Time flies when you’re having … fill in the blank here. Meanwhile, a hazy, muggy morning is unfolding here on the Pharmalot campus, where the official mascot is noisily snoozing and the short people are otherwise gainfully occupied. As for us, we are downing yet another needed cup of stimulation. Our choice today is coconut. No kidding. Feel free to join us, as always. And here are some tidbits to help you along. Have a wonderful day and keep in touch …

A combination of AstraZeneca’s (AZN) lung cancer drug Imfinzi and an experimental treatment failed to extend the lives of patients with stage 4 non-small cell lung cancer and high levels of gene mutations, Reuters reports. The late-stage clinical trial was testing Imfinzi along with another treatment called tremelimumab and compared the combination to platinum-based chemotherapy to treat patients whose cancer had spread beyond the lungs. The study did not meet the main goal of improving overall survival in the primary group.

Continue to STAT Plus to read the full story…

Source link

Related posts

Working Only One Day Each Week Cuts Mental Health Risks By 30%


STAT Plus: Up and down the ladder: The latest comings and goings


Yeast Powered Radiation Detectors to Keep Clinicians Safe


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy